22UA:FRA
BioNTech
85,40 €
arrow_downward
−0,47%(−0,40) 1 D.
10-13, 10:01:35 GMT+2 · EUR
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „22UA“ įžvalgos...
Atidaryti
85,45 €
Aukšta
85,45 €
Žema
85,25 €
Rinkos kapitalizacija
24,08 mlrd.
Vid. kiekis
1,30 tūkst.
Apimtis
58,00
52 sav. aukšta
105,50 €
52 sav. žema
68,00 €
Darbuotojų skaičius
8 tūkst.
Atidaryti
85,45 €
Aukšta
85,45 €
Žema
85,25 €
Rinkos kapitalizacija
24,08 mlrd.
Vid. kiekis
1,30 tūkst.
Apimtis
58,00
52 sav. aukšta
105,50 €
52 sav. žema
68,00 €
Darbuotojų skaičius
8 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Yahoo Finance
·
prieš 1 valandą
Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?
ad-hoc-news.de
·
prieš 2 dienas
BioNTech's 5.4% Friday Rally Came Without a Company Catalyst — and the Insider Trades Kept Coming
Yahoo Finance
·
prieš 1 mėnesį
BioNTech (BNTX) Rallied on Moderna’s Win. Does a Competitor’s Success Validate its Oncology Pipeline?
Profilis
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Apie „BioNTech“
Generalinis direktorius-
Darbuotojai7,81 tūkst.
Įkurta2008
Pagrindinė būstinė-
Sektorius-
Svetainėbiontech.de